Response to: ‘Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus’ by Wang et al,Annals of the Rheumatic Diseases

当前位置： X-MOL 学术 › Ann. Rheum. Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Response to: ‘Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus’ by Wang et al
Annals of the Rheumatic Diseases ( IF 20.3 ) Pub Date : 2021-12-01 , DOI: 10.1136/annrheumdis-2019-216807
Martin Aringer ₁ , Karen Costenbader ₂ , Thomas Dörner ₃ , Sindhu R Johnson ₄

Affiliation

In their letter, Dr Wang and colleagues1 correctly remark that no novel molecular biomarkers were included in the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) 2019 classification criteria for systemic lupus erythematosus (SLE), although a variety of such markers were considered in the process, including the type I interferon signature.2 3 As cited by Wang et …

中文翻译：

回应：Wang 等人的“系统性红斑狼疮诊断基因特征的开发和初步验证”

在他们的信中，Wang 博士及其同事 1 正确地指出，欧洲抗风湿联盟/美国风湿病学会 (EULAR/ACR) 2019 年系统性红斑狼疮 (SLE) 分类标准中没有包含新的分子生物标志物，尽管有多种此类标志物在此过程中考虑了，包括 I 型干扰素特征。2 3 正如 Wang 等人所引用的……

更新日期：2021-11-12

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11